Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

I will also explain why I upgraded OGN stock to buy from hold, despite the additional uncertainty stemming from the Dermavant ...

The FDA has not raised any concerns regarding the safety and efficacy of VTAMA nor have they raised any concerns regarding the approvability of this indication. As part of its review process ...

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Organon (NYSE: OGN), a global healthcare company with a ...

Organon said the Food and Drug Administration extended by three months its review of an application seeking expanded approval of the healthcare company's recently acquired skin-care cream Vtama.

One critical focus for Roivant Sciences is its pipeline. Its success is heavily reliant on products like VTAMA, currently ...

JERSEY CITY, N.J. - Organon (NYSE: OGN), a global healthcare company focused on women's health, announced today that the FDA has extended the review period for the supplemental New Drug Application ...

The FDA has not raised any concerns regarding the safety and efficacy of VTAMA nor have they raised any concerns regarding the approvability of this indication. As part of its review process, the FDA ...

VTAMA: This dermatology product has emerged as a significant growth driver for Organon. Analysts project VTAMA's sales potential to reach $500 million or more, contingent upon successful pediatric ...